Clinical trials: Castration-resistant
Metastatic Castration Resistant Prostate Cancer
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy…
- Trial name
- NCT02566772
- Testing
- TAS3681
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 130 people
- Sponsor
- Taiho Oncology, Inc.
Prostate Adenocarcinoma
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer
- Trial name
- NCT03829930
- Testing
- Entinostat, Enzalutamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- George Washington University
Prostate Cancer
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
- Trial name
- NCT02106507
- Testing
- apalutamide, Everolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC.
- Trial name
- NCT03545165
- Testing
- 177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Metastatic Castration-resistant Prostate Cancer
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.
- Trial name
- NCT04188587
- Testing
- 177 Lu-PSMA-I&T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Castration Resistant Metastatic Prostate Cancer
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment…
- Trial name
- NCT04363164
- Testing
- Testosterone cypionate, Enzalutamide, Testosterone enanthate
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03012321
- Testing
- Olaparib, Abiraterone Acetate, Prednisone
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Prostate Cancer Metastatic
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed.
- Trial name
- NCT03089099
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other…
- Trial name
- NCT07852195
- Testing
- Abiraterone Acetate, Biospecimen Collection, Bone Scan
- Volunteers
- 432 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostatic Neoplasms
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
- Trial name
- NCT04898634
- Testing
- JNJ-78278343
- Where
- 17 sites in United States, China and 4 more
- Volunteers
- 216 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer, MCRPC
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone…
- Trial name
- NCT06890832
- Testing
- 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel
- Volunteers
- 75 people
- Sponsor
- Jina Pharmaceuticals Inc.
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received…
- Trial name
- NCT03834506
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 215 sites in United States, Argentina and 19 more
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
In advanced metastatic castration resistant prostate cancer (mCRPC) progressing after chemotherapy and androgen receptor (AR)-targeted therapy 177Lu-PSMA-617 is an effective treatment.
- Trial name
- NCT06216249
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that…
- Trial name
- NCT06288113
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
TAK-700 in Castration Resistant Prostate Cancer
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who…
- Trial name
- NCT01658527
- Testing
- Orteronel, Bicalutamide
- Where
- 4 sites in Belgium
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Castration Resistant Prostate Cancer
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Background: Prostate cancer does not trigger a strong immune response in the body. Hormone therapy, to reduce levels of testosterone in the body, can be helpful to treat some prostate cancers.
- Trial name
- NCT05445882
- Testing
- Bintrafusp alfa, N-803, BN-Brachyury
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Abiraterone Acetate Trial in African American Prostate Cancer Patients
This is a pilot study of abiraterone acetate in African American/Black patients with castration-resistant prostate cancer. The primary objective is to determine the correlation between germline polymorphisms and antitumor…
- Trial name
- NCT01735396
- Testing
- Abiraterone Acetate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
- Trial name
- NCT06826768
- Testing
- REGN5678, Cemiplimab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Metastatic, Bone Metastases
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included…
- Trial name
- ROTOR (NCT03223597)
- Testing
- Radium-223 dichloride
- Where
- 20 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute